Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Karuna/Vanderbilt, Ipsen/Photocure, Lundbeck/Proximagen

Executive Summary

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.

You may also be interested in...



Cysview’s Safety Information Not Pretty In Pink, FDA Tells Photocure

Discussing a “pinkish tinge to the urine,” rather than blood, overplays the drug’s safety, the agency says in an advertising letter; also, the patient guide further confounds the safety presentation by first mentioning a common adverse reaction to the imaging drug as an uncommon post-marketing event, FDA says.

European Price Cuts, Restructuring Charges, Hit France's Ipsen in 2011

Ipsen's restructuring in France and the U.S, and European austerity measures, lead to a series of charges against 2011 profits, but drug sales increase 5% in the year.

Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?

The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel